Cullinan Therapeutics (CGEM) Long-Term Investments (2021 - 2026)

Cullinan Therapeutics' Long-Term Investments history runs 6 years deep, the most recent figure standing at $38.5 million for Q1 2026.

• In Q1 2026, Long-Term Investments fell 85.16% year-over-year to $38.5 million; the TTM figure through Mar 2026 stood at $38.5 million (down 85.16% YoY), while the FY2025 annual figure was $58.3 million, down 71.5% from the prior year.
• Long-Term Investments for Q1 2026 stood at $38.5 million, down from $58.3 million in the prior quarter.
• The five-year high for Long-Term Investments was $259.4 million in Q1 2025, with the low at $13.5 million in Q3 2023.
• The 5-year median for Long-Term Investments is $69.6 million (2022), against an average of $99.6 million.
• The sharpest annual moves came in 2024 and 2026: Long-Term Investments jumped 328.03% in 2024, then plunged 85.16% in 2026.
• Cullinan Therapeutics' Long-Term Investments stood at $80.9 million in 2022, then sank by 83.25% to $13.5 million in 2023, then surged by 1409.34% to $204.4 million in 2024, then sank by 71.5% to $58.3 million in 2025, then tumbled by 33.93% to $38.5 million in 2026.
• Business Quant data shows CGEM's Long-Term Investments at $38.5 million in Q1 2026, $58.3 million in Q4 2025, and $140.0 million in Q3 2025.